Developer docs
API playgroundTry for free, no card

Search company profiles

Alveo Technologies

Full company profile

uuid0000gpr

Namestring
Alveo Technologies
Legal namestring
Alveo Technologies, Inc.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Alveo Technologies is a private molecular diagnostics company that has developed the Alveo Sense platform — a portable, palm-sized nucleic acid amplification testing (NAAT) system built around a patented method of direct electrical impedance sensing of loop-mediated isothermal amplification (LAMP). The platform eliminates the complex optics used in conventional PCR instruments and is engineered as a solid-state, no-moving-parts aluminum analyzer paired with single-use QR-coded test cartridges (with dried-down reagents and internal process controls) and a Bluetooth-connected iOS/Android mobile app that uploads time- and geo-tagged results to the Alveo Vista cloud portal (Level 3 encryption, 2FA). The system delivers lab-grade molecular results in approximately 45 minutes at the point of need, replacing 2-5 day centralized lab turnaround. Product variants include the Alveo Sense Poultry Avian Influenza Test (H5/H7/H9 multiplex), be.well® for human point-of-care respiratory diagnostics, and an open co-development platform for partners to develop viral, bacterial and fungal assays.

Alveo generates revenue through a razor-and-blade model: one-time sales of the Alveo Analyzer, recurring pull-through consumable cartridge sales, enterprise subscriptions for the Alveo Sense app and Alveo Vista portal, and co-development/licensing partnerships with veterinary, agricultural and bioprocessing organizations; non-dilutive CEPI grant funding supplements R&D. Distribution combines direct enterprise sales with a 23+ country network of named regional distributors across Europe, the Middle East and Africa, anchored by flagship co-development partners Royal GD (Netherlands, veterinary laboratory running 5M+ tests/year) and Global Animal Health (MENA, with a national-scale 1,000-analyzer/10,000-cartridge deployment in Egypt announced December 2025). The company is ISO 13485 certified, CE marked for IVD kits and analyzers, and holds 59 global patents (issued, published or pending) on its core sensing method. Customer segments span animal health (poultry, livestock, companion animals), agriculture and food & beverage, environmental and wastewater surveillance, bioprocess and vaccine manufacturing QC, and human public health.

The company is headquartered in Alameda, California, with 51-100 employees, and is led by CEO Shaun Holt (ex-Illumina, Berkeley Lights, Atonarp), President and CBO Erik Tyrrell-Knott (ex-Thermo Fisher, Mesa Biotech, Atonarp), and CCO Scott Thomas (ex-Illumina, Roche Molecular Diagnostics, Singular Genomics, Seer Bio). Approximately $54 million has been raised across a 2018 round led by Maxim Group with Celesta Capital and Civilization Ventures (~ $38M) and a 2021 round led by Black Diamond Ventures (~$16M), supplemented by a 2026 CEPI development grant for vaccine-manufacturing applications.

Short descriptiontext

Alveo Technologies builds a palm-sized, portable molecular diagnostic platform (Alveo Sense) using patented direct electrical sensing of nucleic acid amplification, delivering lab-grade results in 45 minutes at the point of need for animal health, agriculture, food safety, bioprocessing, and human health customers across 23+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAlameda, United States
HQ citystring
Alameda
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, avian influenza testing, portable PCR devices, point-of-care diagnostics, veterinary diagnostics
Industry3 codes
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACANAE
SaMD – Monitoring, Triage & Risk Stratification Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Molecular Diagnostics
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model5 records
1Hardware Sales (Alveo Analyzer)
TypeHardware Sales
Description

One-time capital equipment sale of the palm-sized, rechargeable Alveo Analyzer (Part Number A-FIN-000039) bundled with USB charging cable and region-specific power adapters. Sold through direct enterprise sales and authorized country distributors.

alveotechnologies.com
2Recurring Consumable Test Cartridge Sales
TypeUsage Based
Description

Recurring pull-through revenue from sale of test-specific Alveo Sense Cartridges (e.g., Avian Influenza Type A/H5/H7 or Type A/H5/H9 panels) consumed with each test run. The Egypt national-scale deployment alone shipped 10,000 test cartridges alongside 1,000 analyzers.

aijourn.com
3Enterprise Subscription for Software Services (be.well / Alveo Sense App / Alveo Vista)
TypeSubscription Recurring
Description

Enterprise customers (e.g., healthcare providers, veterinary organizations) pay or commit to pay a subscription for use of the Services (smartphone app, online platform, cloud data portal). Authorized User access to the Services is dependent on full and timely payment by the affiliated Enterprise Customer.

alveotechnologies.com
4Co-Development and Deployment Partnerships
TypeLicensing Royalties
Description

Strategic collaboration with partners such as Royal GD (Netherlands) and Global Animal Health for joint commercialization, distribution, and expanded testing portfolio development beyond avian influenza. Includes joint go-to-market programs under a Partner Portal structured around Research Use Only and Deployment Partnership tracks.

alveotechnologies.com
5Grant and Non-Dilutive Funding (CEPI)
TypeProfessional Services
Description

Non-dilutive development grant funding from organizations such as the Coalition for Epidemic Preparedness Innovations (CEPI) to explore applying the platform to vaccine manufacturing in-process and QC testing.

prnewswire.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based pricing for Alveo Analyzer and test kits; subscription for software services.
ModelOtherBilling cadenceAnnual
Notes

Pricing is quote-based and not publicly listed. The Alveo Analyzer is sold as a standalone instrument; Alveo Sense test kits (cartridges) are consumables purchased separately. Enterprise customers also pay a subscription for use of the cloud-based Services (Alveo Sense mobile app and Alveo Vista portal). Contact sales@alveotechnologies.com or support@alveotechnologies.com for a quote.

alveotechnologies.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Alveo Sense™
Description

Portable, multiplex-capable molecular diagnostic platform employing a patented method of direct electrical sensing of nucleic acid amplification; marketed across animal health, agriculture, food safety, environment, bioprocessing, and human health use cases.

alveotechnologies.com
+3 more records
Core offering1 text field

Alveo Technologies develops and sells the Alveo Sense™ portable molecular diagnostic platform, anchored by a patented palm-sized Alveo Analyzer that uses direct-electrical-impedance sensing of LAMP-based nucleic-acid amplification. The platform pairs single-use QR-coded test cartridges (initial focus on avian influenza H5/H7/H9 multiplexed panels) with the Alveo Sense mobile app and the Alveo Vista cloud data portal. Its commercial offering extends to the be.well® human point-of-care respiratory diagnostic system and an open development platform that enables partners to co-develop new viral, bacterial, and fungal assays for animal health, agriculture, food and beverage, environmental, and bioprocessing applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 45 minutes to presumptive positive result in on-farm avian influenza testing
+7 more records
Product overview1 text field

Alveo Technologies offers a platform-plus-modules architecture centered on the Alveo Sense™ portable molecular diagnostic platform. The core platform consists of three integrated components: the Alveo Analyzer (a palm-sized, reusable IVD hardware instrument), Alveo Sense Cartridges (single-use, QR-coded test cartridges), and the Alveo Sense Mobile App (a Bluetooth-connected smartphone application). These are complemented by the Alveo Vista™ centralized data analytics portal, which provides cloud-based geotagging, timestamping, and analytics. Built on this platform are specific products including the Alveo Sense Poultry Avian Influenza Test (an H5/H7/H9 multiplexed assay for poultry surveillance), be.well® (a point-of-care respiratory diagnostic system for human health), and an open development platform that enables partners to co-develop new assays for viral, bacterial, and fungal pathogens across animal health, agriculture, environment, food and beverage, and bio-monitoring use cases.

Product and service6 records
1Alveo Analyzer
CategoryCore platform hardware
Description

A standalone, palm-sized, portable, and rechargeable in vitro diagnostic instrument that accepts test-specific Alveo Sense Cartridges and executes nucleic acid amplification and detection using a patented direct electrical sensing method (LAMP-based). It has no moving parts, is housed in a unitary aluminum shell, and pairs with a smartphone via Bluetooth to display test results. It is sold to enterprise customers in animal health, agriculture, public health, bioprocessing, and human health applications.

2Alveo Sense Cartridges
CategoryConsumable test cartridges
Description

Preloaded single-use cartridges with a QR code for secure, automated test registration and result tracking. Reagents for each assay are dried down and packaged with a desiccant for shelf stability, and each cartridge includes internal process controls to ensure tests are run properly. Cartridges support multiplex testing (for example, Avian Influenza Type A with H5/H7 or H9 differentiation) and generate recurring consumable revenue.

3Alveo Sense Poultry Avian Influenza Test
CategoryAvian influenza test kit
Description

A specific test kit using the Alveo Sense platform to detect notifiable Avian Influenza viruses (H5 and H7 subtypes) and the major global endemic strain (H9 subtype), with multiplex differentiation of H5 and H7 or H9 subtypes via direct electrical sensing of nucleic acid amplification. Delivers laboratory-grade results in approximately 45 minutes via the Alveo Sense mobile app for poultry producers, integrators, veterinarians, and regulators managing outbreak containment and routine surveillance.

4be.well® Human Point-of-Care Diagnostic System
CategoryPoint-of-care human diagnostic system
Description

Alveo's branded healthcare solution that brings rapid, accurate molecular diagnostics to clinics, medical offices, and pharmacies. It uses nucleic acid amplification technology to detect a wide range of diseases, bacteria, and other pathogens at the point of care, with an initial focus on respiratory pathogens such as seasonal influenza and Influenza A(H5) (supported by a fulfilled CDC milestone agreement). Sold to healthcare providers, pharmacies, and public-health agencies.

5Alveo Sense Open Development Platform (Assay Co-Development)
CategoryAssay co-development platform
Description

An open-platform program that allows partners to co-develop new molecular assays on the Alveo Sense platform. It supports development across viral, bacterial, and fungal pathogen types and across multiple industries (animal health, agriculture, environment, food and beverage, bio-monitoring). Partners access program resources, technical documentation, and collaboration tools through the Partner Portal, including separate Research Use Only and Deployment Partnership tracks.

6Alveo Vista Centralized Data Portal
CategoryCloud-based data analytics portal (enterprise subscription)
Description

A cloud-based, centralized data portal that automatically geotags and timestamps test results from the Alveo Analyzer and uploads them in real time over Bluetooth for secure, centralized analytics. Access is limited to credentialed users and protected by Level 3 encryption and 2-factor authentication; results can be exported to regulatory agencies and state veterinarians for surveillance and audit. Sold to enterprise customers under an annual subscription.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership17 partners
Strategic tierMajor Non-Dilutive Funding / Strategic Validation PartnerTypeOthersAnnounced on2026-05-26
Description

CEPI awarded Alveo a development grant to explore applying its palm-sized NAAT analyzer, mobile app, and centralized data analytics portal to vaccine manufacturing in-process and QC testing. Marks Alveo's expansion beyond infectious disease diagnostics into the vaccine manufacturing market, supporting animal and human health.

Strategic tierTargeted Co-Development PartnershipTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

Co-developing a rapid molecular diagnostic panel for feline respiratory infections, detecting feline influenza, FCV (feline calicivirus), and FHV (feline herpesvirus). The test is intended for shelters, veterinary clinics, and boarding environments to enable faster diagnosis and treatment.

Strategic tierFlagship / Core Strategic PartnerTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Strategic partnership to deploy Alveo's Alveo Sense Poultry Avian Influenza Test at national scale across Egypt - the first mass-scale use of on-site real-time molecular diagnostics for poultry disease monitoring globally. Initial deployment of 1,000 analyzers and 10,000 test cartridges covering ~10% of farms along major migratory bird flyways, with plans to expand across the Middle East and North Africa. Results delivered in approximately 45 minutes with wireless real-time data upload. GAH also serves as Alveo's distributor across Bahrain, Egypt, Oman, and Saudi Arabia.

Strategic tierValidation / Reference PartnerTypeTechnology or IntegrationAnnounced on2025-10-23
Description

JGI evaluated Alveo's portable Alveo Sense™ molecular testing platform for wastewater-based pathogen surveillance, demonstrating feasibility for rapid, on-site infectious disease monitoring. Validation expands potential applications of the platform beyond laboratory settings.

5Poultry Diagnostics Research Center (PDRC), University of Georgia College of Veterinary Medicine
Strategic tierCore Scientific Validation PartnerTypeStrategic or Co-development PartnerAnnounced on2025-08-05
Description

Two-phase research study validating Alveo Sense Poultry Avian Influenza Test performance in detecting high and low pathogenic H5N1 in experimentally infected chickens and ducks. PDRC found >99% accuracy in Type A and H5 detection, including from pooled cloacal swabs in ducks. Dr. Daniel Perez has presented results at the 15th International Seminar on Poultry Pathology and Production and FAO meetings.

alveotechnologies.com
Strategic tierFlagship / Core Strategic PartnerTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Royal GD, based in Deventer, Netherlands, is one of the world's largest veterinary diagnostic laboratories (5M+ tests/year). Co-developed the Alveo Sense™ Poultry Avian Influenza Test combining Alveo's molecular platform with Royal GD's veterinary expertise. Collaboration is being expanded beyond avian influenza into additional notifiable disease and respiratory targets impacting poultry. Royal GD also serves as Alveo's Netherlands distributor and co-presents webinars (e.g., Professor Sjaak De Wit).

7U.S. Centers for Disease Control and Prevention (CDC)
Strategic tierMajor Reference / Validation PartnerTypeOthersAnnounced on2025-01-01
Description

Alveo successfully fulfilled an expanded CDC milestone agreement to advance its rapid molecular test for detecting and differentiating between seasonal Influenzas A, B, and A(H5) in humans. The CDC relationship underpins Alveo's be.well® human-health diagnostics pipeline.

alveotechnologies.com
Strategic tierAuthorized Media Relations PartnerTypeGTM or Marketing Partner
Description

Spectrum Science is Alveo's authorized media relations partner. Media inquiries are routed to Alveo1@spectrumscience.com, supporting PR and earned-media activities around press releases, CEPI grant, Egypt deployment, PDRC results, and CDC milestones.

9Shehdula sh.p.k
Strategic tierCountry Distributor (Albania)TypeChannel Partner/ Reseller/ Distributor
Description

Alveo's authorized distributor in Albania (dardan@shehdula.com, +355 694 093 809).

alveotechnologies.com
Strategic tierCountry Distributor (Baltics)TypeChannel Partner/ Reseller/ Distributor
Description

Alveo's authorized distributor in Estonia, Latvia, and Lithuania (info@hydrox.lv, +371 67551517).

Strategic tierCountry Distributor (Hungary)TypeChannel Partner/ Reseller/ Distributor
Description

Alveo's authorized distributor in Hungary (info@biosan.hu, +36 70 312 93 73).

Strategic tierCountry Distributor (Montenegro)TypeChannel Partner/ Reseller/ Distributor
Description

Alveo's authorized distributor in Montenegro (interpharm@interpharm.me, +382 20 675 090).

13Kubbar International
Strategic tierCountry Distributor (Kuwait)TypeChannel Partner/ Reseller/ Distributor
Description

Alveo's authorized distributor in Kuwait (gasser.ziad@kubbarintl.com, +971 42204761).

alveotechnologies.com
Strategic tierCountry Distributor (Pakistan)TypeChannel Partner/ Reseller/ Distributor
Description

Alveo's authorized distributor in Pakistan (Hivet@brain.net.pk, +92 321 4380690).

Strategic tierCountry Distributor (Qatar)TypeChannel Partner/ Reseller/ Distributor
Description

Alveo's authorized distributor in Qatar (suwaidi1@qatar.net.qa, +974 44995121).

Strategic tierCountry Distributor (Morocco)TypeChannel Partner/ Reseller/ Distributor
Description

Alveo's authorized distributor in Morocco (contact@cylcopharma.ma, +212 5 20 30 11 90).

Strategic tierCountry Distributor (Tunisia)TypeChannel Partner/ Reseller/ Distributor
Description

Alveo's authorized distributor in Tunisia (yousra.z@wafalab.com, +216 29 29 32 32).

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Established molecular diagnostics incumbent (GeneXpert system) with deep hospital, clinic, and reference-lab penetration. Directly comparable to Alveo as a molecular NAAT platform, but Cepheid operates at higher throughput and price points with a much larger installed base.

TypeDirect peer
Description

Acquired by Thermo Fisher in 2021, Mesa Biotech developed the Accula line of LAMP-based, palm-sized molecular diagnostics for point-of-care use — the closest historical analog to Alveo's be.well / Alveo Sense platform in chemistry, form factor, and target customer.

3Abbott (ID NOW)
TypeBroad incumbent
Description

ID NOW is Abbott's rapid molecular point-of-care platform for influenza, RSV, and Strep A. Comparable to Alveo in delivering lab-grade molecular results at the point of need, but Abbott operates at far greater scale with established reimbursement and clinical channels.

TypeBroad incumbent
Description

BioFire FilmArray is the leading syndromic molecular diagnostic panel in clinical labs and increasingly in decentralized settings. Comparable to Alveo as a multiplex NAAT platform, though BioFire targets higher-complexity clinical settings versus Alveo's field / point-of-need positioning.

5Cue Health
TypeDirect peer
Description

Cue's portable, consumer- and clinician-facing molecular diagnostic platform (Cue Reader + test cartridges) targets respiratory pathogens at point-of-care. Closely comparable to be.well in form factor, cartridge model, and direct-to-provider GTM.

TypeDirect peer
Description

Visby develops single-use, palm-sized PCR diagnostic devices for infectious disease at point-of-care. Comparable to Alveo Sense as a portable molecular platform competing on miniaturization and time-to-result, with a similar hardware-plus-consumable revenue model.

TypeBroad incumbent
Description

QuidelOrtho (Triage MeterPro, Sofia, QuickVue) is a broad rapid-diagnostics incumbent with growing molecular and immunoassay offerings. Comparable to Alveo as a decentralized infectious-disease testing provider, but with deeper reimbursement, distribution, and clinical relationships.

TypeEmerging player
Description

Co-Diagnostics develops and commercializes PCR and LAMP-based molecular diagnostics including the Logix Smart platform. Comparable to Alveo in LAMP chemistry and infectious-disease focus, though historically more concentrated on COVID and clinical lab use.

9Lucira Health (now Pfizer)
TypeDirect peer
Description

Lucira (acquired by Pfizer in 2023) developed a LAMP-based, single-use at-home molecular COVID and flu test. Directly comparable to Alveo's LAMP chemistry and decentralized-use model, illustrating both the opportunity and the execution risk for handheld molecular platforms.

TypeEmerging player
Description

T2 develops proprietary molecular diagnostics platforms (T2 Magnetic Resonance) for sepsis and Candida directly from whole blood. Comparable to Alveo as a molecular platform company targeting decentralized, rapid diagnostics, though in a different clinical vertical.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alveo Technologies

Molecular Diagnosticsalveotechnologies.com

Alveo Technologies builds a palm-sized, portable molecular diagnostic platform (Alveo Sense) using patented direct electrical sensing of nucleic acid amplification, delivering lab-grade results in 45 minutes at the point of need for animal health, agriculture, food safety, bioprocessing, and human health customers across 23+ countries.

What Alveo Technologies does

Alveo Technologies is a private molecular diagnostics company that has developed the Alveo Sense platform — a portable, palm-sized nucleic acid amplification testing (NAAT) system built around a patented method of direct electrical impedance sensing of loop-mediated isothermal amplification (LAMP). The platform eliminates the complex optics used in conventional PCR instruments and is engineered as a solid-state, no-moving-parts aluminum analyzer paired with single-use QR-coded test cartridges (with dried-down reagents and internal process controls) and a Bluetooth-connected iOS/Android mobile app that uploads time- and geo-tagged results to the Alveo Vista cloud portal (Level 3 encryption, 2FA). The system delivers lab-grade molecular results in approximately 45 minutes at the point of need, replacing 2-5 day centralized lab turnaround. Product variants include the Alveo Sense Poultry Avian Influenza Test (H5/H7/H9 multiplex), be.well® for human point-of-care respiratory diagnostics, and an open co-development platform for partners to develop viral, bacterial and fungal assays.

Alveo generates revenue through a razor-and-blade model: one-time sales of the Alveo Analyzer, recurring pull-through consumable cartridge sales, enterprise subscriptions for the Alveo Sense app and Alveo Vista portal, and co-development/licensing partnerships with veterinary, agricultural and bioprocessing organizations; non-dilutive CEPI grant funding supplements R&D. Distribution combines direct enterprise sales with a 23+ country network of named regional distributors across Europe, the Middle East and Africa, anchored by flagship co-development partners Royal GD (Netherlands, veterinary laboratory running 5M+ tests/year) and Global Animal Health (MENA, with a national-scale 1,000-analyzer/10,000-cartridge deployment in Egypt announced December 2025). The company is ISO 13485 certified, CE marked for IVD kits and analyzers, and holds 59 global patents (issued, published or pending) on its core sensing method. Customer segments span animal health (poultry, livestock, companion animals), agriculture and food & beverage, environmental and wastewater surveillance, bioprocess and vaccine manufacturing QC, and human public health.

The company is headquartered in Alameda, California, with 51-100 employees, and is led by CEO Shaun Holt (ex-Illumina, Berkeley Lights, Atonarp), President and CBO Erik Tyrrell-Knott (ex-Thermo Fisher, Mesa Biotech, Atonarp), and CCO Scott Thomas (ex-Illumina, Roche Molecular Diagnostics, Singular Genomics, Seer Bio). Approximately $54 million has been raised across a 2018 round led by Maxim Group with Celesta Capital and Civilization Ventures (~ $38M) and a 2021 round led by Black Diamond Ventures (~$16M), supplemented by a 2026 CEPI development grant for vaccine-manufacturing applications.

Alveo Technologies firmographics

Firmographics
Name
Alveo Technologies
Legal name
Alveo Technologies, Inc.
Website
https://alveotechnologies.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Alveo Technologies builds a palm-sized, portable molecular diagnostic platform (Alveo Sense) using patented direct electrical sensing of nucleic acid amplification, delivering lab-grade results in 45 minutes at the point of need for animal health, agriculture, food safety, bioprocessing, and human health customers across 23+ countries.
Ownership category
akta.pro rank

Alveo Technologies industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACANAE
SaMD – Monitoring, Triage & Risk Stratification Software
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • Molecular diagnostics
  • Avian influenza testing
  • Portable PCR devices
  • Point-of-care diagnostics
  • Veterinary diagnostics

Where Alveo Technologies is headquartered

Location

Headquarters

HQ city
Alameda
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Alveo Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Hardware Sales (Alveo Analyzer): One-time capital equipment sale of the palm-sized, rechargeable Alveo Analyzer (Part Number A-FIN-000039) bundled with USB charging cable and region-specific power adapters. Sold through direct enterprise sales and authorized country distributors.
  2. Recurring Consumable Test Cartridge Sales: Recurring pull-through revenue from sale of test-specific Alveo Sense Cartridges (e.g., Avian Influenza Type A/H5/H7 or Type A/H5/H9 panels) consumed with each test run. The Egypt national-scale deployment alone shipped 10,000 test cartridges alongside 1,000 analyzers.
  3. Enterprise Subscription for Software Services (be.well / Alveo Sense App / Alveo Vista): Enterprise customers (e.g., healthcare providers, veterinary organizations) pay or commit to pay a subscription for use of the Services (smartphone app, online platform, cloud data portal). Authorized User access to the Services is dependent on full and timely payment by the affiliated Enterprise Customer.
  4. Co-Development and Deployment Partnerships: Strategic collaboration with partners such as Royal GD (Netherlands) and Global Animal Health for joint commercialization, distribution, and expanded testing portfolio development beyond avian influenza. Includes joint go-to-market programs under a Partner Portal structured around Research Use Only and Deployment Partnership tracks.
  5. Grant and Non-Dilutive Funding (CEPI): Non-dilutive development grant funding from organizations such as the Coalition for Epidemic Preparedness Innovations (CEPI) to explore applying the platform to vaccine manufacturing in-process and QC testing.

Pricing tiers

ModelBillingPrice
OtherAnnualQuote-based pricing for Alveo Analyzer and test kits; subscription for software services.

Go-to-market motion4 records

Distribution channels6 records

Marketing channels9 records

Alveo Technologies product offering

Product offering

Core offering

Alveo Technologies develops and sells the Alveo Sense™ portable molecular diagnostic platform, anchored by a patented palm-sized Alveo Analyzer that uses direct-electrical-impedance sensing of LAMP-based nucleic-acid amplification. The platform pairs single-use QR-coded test cartridges (initial focus on avian influenza H5/H7/H9 multiplexed panels) with the Alveo Sense mobile app and the Alveo Vista cloud data portal. Its commercial offering extends to the be.well® human point-of-care respiratory diagnostic system and an open development platform that enables partners to co-develop new viral, bacterial, and fungal assays for animal health, agriculture, food and beverage, environmental, and bioprocessing applications.

Product overview

Alveo Technologies offers a platform-plus-modules architecture centered on the Alveo Sense™ portable molecular diagnostic platform. The core platform consists of three integrated components: the Alveo Analyzer (a palm-sized, reusable IVD hardware instrument), Alveo Sense Cartridges (single-use, QR-coded test cartridges), and the Alveo Sense Mobile App (a Bluetooth-connected smartphone application). These are complemented by the Alveo Vista™ centralized data analytics portal, which provides cloud-based geotagging, timestamping, and analytics. Built on this platform are specific products including the Alveo Sense Poultry Avian Influenza Test (an H5/H7/H9 multiplexed assay for poultry surveillance), be.well® (a point-of-care respiratory diagnostic system for human health), and an open development platform that enables partners to co-develop new assays for viral, bacterial, and fungal pathogens across animal health, agriculture, environment, food and beverage, and bio-monitoring use cases.

Differentiator

Problem solved

Functional benefit

Brands

  • Alveo Sense™: Portable, multiplex-capable molecular diagnostic platform employing a patented method of direct electrical sensing of nucleic acid amplification; marketed across animal health, agriculture, food safety, environment, bioprocessing, and human health use cases.
  • be.well®
  • Alveo Vista™
  • Alveo Analyzer

Products and services

  • Alveo Analyzer A standalone, palm-sized, portable, and rechargeable in vitro diagnostic instrument that accepts test-specific Alveo Sense Cartridges and executes nucleic acid amplification and detection using a patented direct electrical sensing method (LAMP-based). It has no moving parts, is housed in a unitary aluminum shell, and pairs with a smartphone via Bluetooth to display test results. It is sold to enterprise customers in animal health, agriculture, public health, bioprocessing, and human health applications.
  • Alveo Sense Cartridges Preloaded single-use cartridges with a QR code for secure, automated test registration and result tracking. Reagents for each assay are dried down and packaged with a desiccant for shelf stability, and each cartridge includes internal process controls to ensure tests are run properly. Cartridges support multiplex testing (for example, Avian Influenza Type A with H5/H7 or H9 differentiation) and generate recurring consumable revenue.
  • Alveo Sense Poultry Avian Influenza Test A specific test kit using the Alveo Sense platform to detect notifiable Avian Influenza viruses (H5 and H7 subtypes) and the major global endemic strain (H9 subtype), with multiplex differentiation of H5 and H7 or H9 subtypes via direct electrical sensing of nucleic acid amplification. Delivers laboratory-grade results in approximately 45 minutes via the Alveo Sense mobile app for poultry producers, integrators, veterinarians, and regulators managing outbreak containment and routine surveillance.
  • be.well® Human Point-of-Care Diagnostic System Alveo's branded healthcare solution that brings rapid, accurate molecular diagnostics to clinics, medical offices, and pharmacies. It uses nucleic acid amplification technology to detect a wide range of diseases, bacteria, and other pathogens at the point of care, with an initial focus on respiratory pathogens such as seasonal influenza and Influenza A(H5) (supported by a fulfilled CDC milestone agreement). Sold to healthcare providers, pharmacies, and public-health agencies.
  • Alveo Sense Open Development Platform (Assay Co-Development) An open-platform program that allows partners to co-develop new molecular assays on the Alveo Sense platform. It supports development across viral, bacterial, and fungal pathogen types and across multiple industries (animal health, agriculture, environment, food and beverage, bio-monitoring). Partners access program resources, technical documentation, and collaboration tools through the Partner Portal, including separate Research Use Only and Deployment Partnership tracks.
  • Alveo Vista Centralized Data Portal A cloud-based, centralized data portal that automatically geotags and timestamps test results from the Alveo Analyzer and uploads them in real time over Bluetooth for secure, centralized analytics. Access is limited to credentialed users and protected by Level 3 encryption and 2-factor authentication; results can be exported to regulatory agencies and state veterinarians for surveillance and audit. Sold to enterprise customers under an annual subscription.

Quantifiable outcome

  • 45 minutes to presumptive positive result in on-farm avian influenza testing
  • +7 more outcomes

Companies that use Alveo Technologies

Customer profile

Segments6 records

Ideal customer profiles5 records

Alveo Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Alveo Technologies partnerships and signals

Strategic signal

Partnerships

17 partnerships are on record, tiered major non-dilutive funding / strategic validation partner, targeted co-development partnership, flagship / core strategic partner, validation / reference partner, core scientific validation partner, major reference / validation partner, authorized media relations partner, country distributor (albania), country distributor (baltics), country distributor (hungary), country distributor (montenegro), country distributor (kuwait), country distributor (pakistan), country distributor (qatar), country distributor (morocco) and country distributor (tunisia).

  • Coalition for Epidemic Preparedness Innovations (CEPI)major non-dilutive funding / strategic validation partnerOthers · 26 May 2026CEPI awarded Alveo a development grant to explore applying its palm-sized NAAT analyzer, mobile app, and centralized data analytics portal to vaccine manufacturing in-process and QC testing. Marks Alveo's expansion beyond infectious disease diagnostics into the vaccine manufacturing market, supporting animal and human health.
  • Fraunhofer Institutetargeted co-development partnershipStrategic or Co-development Partner · 9 April 2026Co-developing a rapid molecular diagnostic panel for feline respiratory infections, detecting feline influenza, FCV (feline calicivirus), and FHV (feline herpesvirus). The test is intended for shelters, veterinary clinics, and boarding environments to enable faster diagnosis and treatment.
  • Global Animal Health (GAH)flagship / core strategic partnerStrategic or Co-development Partner · 18 December 2025Strategic partnership to deploy Alveo's Alveo Sense Poultry Avian Influenza Test at national scale across Egypt - the first mass-scale use of on-site real-time molecular diagnostics for poultry disease monitoring globally. Initial deployment of 1,000 analyzers and 10,000 test cartridges covering ~10% of farms along major migratory bird flyways, with plans to expand across the Middle East and North Africa. Results delivered in approximately 45 minutes with wireless real-time data upload. GAH also serves as Alveo's distributor across Bahrain, Egypt, Oman, and Saudi Arabia.
  • U.S. Department of Energy Joint Genome Institute (JGI), Lawrence Berkeley National Laboratoryvalidation / reference partnerTechnology or Integration · 23 October 2025JGI evaluated Alveo's portable Alveo Sense™ molecular testing platform for wastewater-based pathogen surveillance, demonstrating feasibility for rapid, on-site infectious disease monitoring. Validation expands potential applications of the platform beyond laboratory settings.
  • Poultry Diagnostics Research Center (PDRC), University of Georgia College of Veterinary Medicinecore scientific validation partnerStrategic or Co-development Partner · 5 August 2025Two-phase research study validating Alveo Sense Poultry Avian Influenza Test performance in detecting high and low pathogenic H5N1 in experimentally infected chickens and ducks. PDRC found >99% accuracy in Type A and H5 detection, including from pooled cloacal swabs in ducks. Dr. Daniel Perez has presented results at the 15th International Seminar on Poultry Pathology and Production and FAO meetings.
  • Royal GD (GD Animal Health)flagship / core strategic partnerStrategic or Co-development Partner · 1 January 2025Royal GD, based in Deventer, Netherlands, is one of the world's largest veterinary diagnostic laboratories (5M+ tests/year). Co-developed the Alveo Sense™ Poultry Avian Influenza Test combining Alveo's molecular platform with Royal GD's veterinary expertise. Collaboration is being expanded beyond avian influenza into additional notifiable disease and respiratory targets impacting poultry. Royal GD also serves as Alveo's Netherlands distributor and co-presents webinars (e.g., Professor Sjaak De Wit).
  • U.S. Centers for Disease Control and Prevention (CDC)major reference / validation partnerOthers · 1 January 2025Alveo successfully fulfilled an expanded CDC milestone agreement to advance its rapid molecular test for detecting and differentiating between seasonal Influenzas A, B, and A(H5) in humans. The CDC relationship underpins Alveo's be.well® human-health diagnostics pipeline.
  • Spectrum Scienceauthorized media relations partnerGTM or Marketing PartnerSpectrum Science is Alveo's authorized media relations partner. Media inquiries are routed to Alveo1@spectrumscience.com, supporting PR and earned-media activities around press releases, CEPI grant, Egypt deployment, PDRC results, and CDC milestones.
  • Shehdula sh.p.kcountry distributor (albania)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Albania (dardan@shehdula.com, +355 694 093 809).
  • Sia Hydroxcountry distributor (baltics)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Estonia, Latvia, and Lithuania (info@hydrox.lv, +371 67551517).
  • Biosan Kft.country distributor (hungary)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Hungary (info@biosan.hu, +36 70 312 93 73).
  • InterPharm D.o.o.country distributor (montenegro)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Montenegro (interpharm@interpharm.me, +382 20 675 090).
  • Kubbar Internationalcountry distributor (kuwait)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Kuwait (gasser.ziad@kubbarintl.com, +971 42204761).
  • Hivet Internationalcountry distributor (pakistan)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Pakistan (Hivet@brain.net.pk, +92 321 4380690).
  • Ali Al Suwaidi Trading Establishment (ASTE)country distributor (qatar)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Qatar (suwaidi1@qatar.net.qa, +974 44995121).
  • Cyclopharma S.A.country distributor (morocco)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Morocco (contact@cylcopharma.ma, +212 5 20 30 11 90).
  • Wafalabcountry distributor (tunisia)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Tunisia (yousra.z@wafalab.com, +216 29 29 32 32).

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Alveo Technologies competitors and assessment

Company assessment

Broad incumbents

  • Cepheid (Danaher): Established molecular diagnostics incumbent (GeneXpert system) with deep hospital, clinic, and reference-lab penetration. Directly comparable to Alveo as a molecular NAAT platform, but Cepheid operates at higher throughput and price points with a much larger installed base.
  • Abbott (ID NOW): ID NOW is Abbott's rapid molecular point-of-care platform for influenza, RSV, and Strep A. Comparable to Alveo in delivering lab-grade molecular results at the point of need, but Abbott operates at far greater scale with established reimbursement and clinical channels.
  • bioMérieux (BioFire): BioFire FilmArray is the leading syndromic molecular diagnostic panel in clinical labs and increasingly in decentralized settings. Comparable to Alveo as a multiplex NAAT platform, though BioFire targets higher-complexity clinical settings versus Alveo's field / point-of-need positioning.
  • QuidelOrtho: QuidelOrtho (Triage MeterPro, Sofia, QuickVue) is a broad rapid-diagnostics incumbent with growing molecular and immunoassay offerings. Comparable to Alveo as a decentralized infectious-disease testing provider, but with deeper reimbursement, distribution, and clinical relationships.

Direct peers

  • Mesa Labs / Mesa Biotech (acquired by Thermo Fisher Scientific): Acquired by Thermo Fisher in 2021, Mesa Biotech developed the Accula line of LAMP-based, palm-sized molecular diagnostics for point-of-care use — the closest historical analog to Alveo's be.well / Alveo Sense platform in chemistry, form factor, and target customer.
  • Cue Health: Cue's portable, consumer- and clinician-facing molecular diagnostic platform (Cue Reader + test cartridges) targets respiratory pathogens at point-of-care. Closely comparable to be.well in form factor, cartridge model, and direct-to-provider GTM.
  • Visby Medical: Visby develops single-use, palm-sized PCR diagnostic devices for infectious disease at point-of-care. Comparable to Alveo Sense as a portable molecular platform competing on miniaturization and time-to-result, with a similar hardware-plus-consumable revenue model.
  • Lucira Health (now Pfizer): Lucira (acquired by Pfizer in 2023) developed a LAMP-based, single-use at-home molecular COVID and flu test. Directly comparable to Alveo's LAMP chemistry and decentralized-use model, illustrating both the opportunity and the execution risk for handheld molecular platforms.

Emerging players

  • Co-Diagnostics (Codi): Co-Diagnostics develops and commercializes PCR and LAMP-based molecular diagnostics including the Logix Smart platform. Comparable to Alveo in LAMP chemistry and infectious-disease focus, though historically more concentrated on COVID and clinical lab use.
  • T2 Biosystems: T2 develops proprietary molecular diagnostics platforms (T2 Magnetic Resonance) for sepsis and Candida directly from whole blood. Comparable to Alveo as a molecular platform company targeting decentralized, rapid diagnostics, though in a different clinical vertical.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Alveo Technologies social profiles

Digital presence

Alveo Technologies compliance and trust

Trust signal

Compliance5 records

Alveo Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alveo Technologies leadership team

Management profile

Number of profiles

Profiles3 records

Alveo Technologies subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Alveo Technologies funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alveo Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alveo Technologies

What does Alveo Technologies do?

Alveo Technologies develops and sells the Alveo Sense™ portable molecular diagnostic platform, anchored by a patented palm-sized Alveo Analyzer that uses direct-electrical-impedance sensing of LAMP-based nucleic-acid amplification. The platform pairs single-use QR-coded test cartridges (initial focus on avian influenza H5/H7/H9 multiplexed panels) with the Alveo Sense mobile app and the Alveo Vista cloud data portal. Its commercial offering extends to the be.well® human point-of-care respiratory diagnostic system and an open development platform that enables partners to co-develop new viral, bacterial, and fungal assays for animal health, agriculture, food and beverage, environmental, and bioprocessing applications.

Is Alveo Technologies a public or private company?

Alveo Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Alveo Technologies founded?

Alveo Technologies was founded in 2015. It employs 51 to 100 people.

Where is Alveo Technologies based?

Alveo Technologies is headquartered in Alameda, United States, in the North America region.

How does Alveo Technologies make money?

Five revenue lines are on record. Hardware Sales (Alveo Analyzer) is the primary driver. The others are recurring Consumable Test Cartridge Sales, enterprise Subscription for Software Services (be.well / Alveo Sense App / Alveo Vista), co-Development and Deployment Partnerships and grant and Non-Dilutive Funding (CEPI).

Who are Alveo Technologies's main competitors?

Broad incumbents on record are Cepheid (Danaher), Abbott (ID NOW), bioMérieux (BioFire) and QuidelOrtho. Direct peers are Mesa Labs / Mesa Biotech (acquired by Thermo Fisher Scientific), Cue Health, Visby Medical and Lucira Health (now Pfizer). Emerging players are Co-Diagnostics (Codi) and T2 Biosystems.

Does Alveo Technologies have an API?

No public API is recorded for Alveo Technologies.

What industry is Alveo Technologies in?

Alveo Technologies's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLACANAE, SaMD – Monitoring, Triage & Risk Stratification Software. Its NAICS code is 325413 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAlveo Technologies and Royal GD Expand Partnership to Advance Point of Need Molecular Diagnostics to Additional Livestock Species & Expanded Poultry OfferingsAlveo Technologies and Royal GD expanded their partnership to develop molecular tests for swine, cattle, and poultry, building on 18 months of avian influenza testing. Royal GD will commit new R&D resources, and the companies expect to expand their offering by 2027.PR NewswireAlveo Technologies Partners with Alliance Global (AGBL) to Expand Access to Avian Influenza Testing Across Africa, Central Asia and a Portion of the Eastern MediterraneanAlveo Technologies announced a distribution agreement with Alliance Global to bring its Alveo Sense Poultry avian influenza test to farmers and health officials across Africa, Central Asia, and select Eastern Mediterranean countries. The test has detected over 208 million domestic birds in the U.S. alone and at least 633 million globally. The partnership expands Alveo's global reach for point-of-need diagnostics.AgFunderNewsCan smarter surveillance help poultry farms catch bird flu earlier?Alveo Technologies and AgriNerds have partnered to combine AgriNerds' waterfowl risk-prediction network with Alveo's portable molecular diagnostics, which detects avian flu in 45 minutes. Alveo's test distinguishes H5 and H7 subtypes at 96-99% accuracy and is expected to receive USDA approval in Q4.PR NewswireAlveo Technologies Partners with AgriNerds to Create First-of-its-Kind, Dynamic Avian Influenza Surveillance System for U.S. Poultry FarmersAlveo Technologies and AgriNerds partnered to create a dynamic avian influenza surveillance system for U.S. poultry farmers, combining Alveo's rapid molecular testing with AgriNerds' Waterfowl Alert Network. The system generates daily risk scores based on remote sensing and alerts farmers to conduct targeted testing, which can detect the virus in under an hour. The partnership aims to lower costs and improve early detection.Clinical Lab ProductsAlveo, UTMB Develop Point-of-Care Lassa Fever Test for West AfricaAlveo Technologies and the University of Texas Medical Branch (UTMB) have formed a partnership to develop point-of-care diagnostics for Lassa fever, targeting deployment in Nigeria and Sierra Leone. The initiative aims to replace weeks-long laboratory processes with real-time pathogen detection to improve outbreak containment and patient management in West Africa. Additionally, the collaboration includes validating the technology's resilience through field testing in Peru and high-containment studies at UTMB.PR NewswireAlveo Technologies Partners with University of Texas Medical Branch (UTMB) to Develop Point-of-Care Diagnostics for Lassa Fever in West AfricaAlveo Technologies announced a strategic partnership with the University of Texas Medical Branch (UTMB) to develop point-of-care diagnostics for Lassa fever in West Africa. The initiative aims to deploy real-time pathogen detection at clinical sites in Nigeria and Sierra Leone to improve outbreak containment and patient management. This collaboration also includes validation initiatives for avian influenza surveillance in Peru and high-containment testing at UTMB's Galveston National Laboratory.PR NewswireAlveo Technologies Secures CEPI Grant to Transform Vaccine Manufacturing Speed and AffordabilityAlveo Technologies has been awarded a grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to explore how its molecular detection platform, currently used for pathogen detection globally, can be applied to vaccine manufacturing. The award marks Alveo's entry into the vaccine manufacturing market, extending its technology beyond infectious disease diagnostics into supporting animal and human health. The platform integrates a palm-sized analyzer, mobile app, and data analytics portal designed to streamline in-process testing and quality control workflows while reducing costs.DVM 360A rapid, molecular feline respiratory panel diagnostic is being developedAlveo Technologies Inc and the Fraunhofer Institute for Cell Therapy and Immunology IZI have partnered to develop a rapid molecular diagnostic panel that simultaneously detects feline influenza, feline calicivirus, and feline herpes virus-1 infections. The test, based on Alveo's IntelliSense platform, would deliver results in minutes compared to current laboratory tests that can take up to a week. Early and accurate diagnosis would enable faster treatment for sick cats and allow animal shelters to isolate infected animals sooner, reducing the need for weeks-long quarantine periods and freeing up capacity.PR NewswireAlveo Technologies und Global Animal Health schließen Partnerschaft zur Einführung einer landesweiten molekularen Überwachung der Vogelgrippe in ÄgyptenAlveo Technologies announced a strategic partnership with Global Animal Health (GAH) to deploy its Alveo Sense Poultry Avian Influenza Test at scale across Egypt, marking the first large-scale use of decentralized molecular point-of-need diagnostics for avian flu surveillance globally.PR NewswireAlveo Technologies et Global Animal Health s'associent pour déployer une surveillance moléculaire de la grippe aviaire à l'échelle nationale en ÉgypteAlveo Technologies announced a strategic partnership with Global Animal Health (GAH) to deploy its Alveo Sense avian influenza test at scale across Egypt, marking the first large-scale use of on-site, real-time molecular diagnostics for poultry disease surveillance. The initial deployment includes 1,000 Alveo Sense analyzers and 10,000 test cartridges, covering approximately 10% of farms along major bird migration routes, with plans to extend the technology across the Middle East and North Africa. Egypt becomes the first country globally to adopt the Alveo Sense platform at this distribution level, establishing a national disease surveillance and rapid-response model for the poultry sector.